Enasidenib mesylate

产品说明书

Print
Chemical Structure| 1650550-25-6 同义名 : AG-221 mesylate; Idhifa
CAS号 : 1650550-25-6
货号 : A483204
分子式 : C20H21F6N7O4S
纯度 : 99%+
分子量 : 569.48
MDL号 : N/A
存储条件：

Pure form Inert atmosphere, 2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(184.38 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
生物活性
描述 Enasidenib (AG-221) counteracts the alterations induced by mutant IDH2 on DNA methylation in mutant stem/progenitor cells, fostering differentiation and inhibiting the self-renewal capabilities of IDH2-mutant leukemia cells. These effects are notably intensified when Flt3ITD is concurrently inhibited. Enasidenib therapy leads to leukemic cell differentiation, evidenced by an increased CD11b+ population and a decreased c-Kit+ population in the peripheral blood within 2 weeks[2].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.76mL

0.35mL

0.18mL

8.78mL

1.76mL

0.88mL

17.56mL

3.51mL

1.76mL
参考文献

[1]Exploring the Pathway: IDH Mutations and Metabolic Dysregulation in Cancer Cells: A Novel Therapeutic Target. MAY 29, 2015

[2]Alan H. Shih, et al. AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo. Blood 2014 124:437.